Viatris (VTRS)
Health Care · Pharmaceutical Manufacturing and Distribution
A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more than 165 countries.
What Viatris does
Viatris is a global healthcare company that develops, manufactures, and distributes a diversified portfolio of medicines including generics, branded products, and innovative therapeutics. The company supplies medicines to approximately 1 billion patients worldwide annually, operating in more than 165 countries with 27 manufacturing and distribution sites and over 1,400 approved molecules. Viatris maintains a global supply chain and scientific expertise across multiple therapeutic areas, serving both developed and emerging markets through three primary geographic segments.
Themes: ["Generic drugs / biosimilars","Innovative pipeline development","Global supply chain / manufacturing","Emerging markets expansion","Strategic divestitures / portfolio rationalization","Women's health","Cardiovascular therapeutics"]
Fundamentals
- Price$16.66 as of 2026-07-08 close
- Market cap$19.9B as of 2026-07-09
- 1-year return+79.9% as of 2026-07-08 close
- Net margin-2.0% as of 2026-07-09
- Gross margin+39.8% as of 2026-07-09
- ROE-2.0% as of 2026-07-09
- Debt / equity0.98 as of 2026-07-09
- Revenue growth (YoY)+1.6% as of 2026-07-09
- Revenue CAGR (3y)-4.2% SEC XBRL
- Beta0.91 as of 2026-07-09
Dividend: yield +3.1%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Company is currently unprofitable with negative net margin of -2.04%, presenting near-term earnings pressure despite 1.62% revenue growth","Significant ongoing debt reduction requirements and maximum leverage ratio covenants that constrain financial flexibility and capital allocation","Pipeline execution risk: multiple Phase 3 programs require regulatory approval and commercialization success (meloxicam, contraceptive patch, selatogrel, cenerimod) to drive future growth"]
Competitors & peers
- Teva Pharmaceutical Industries
- Sandoz (Novartis)
- Hikma Pharmaceuticals
- Aurobindo Pharma
- Sun Pharmaceutical
- Dr. Reddy's Laboratories
- Lupin Limited
- Cipla Limited
- Global pharmaceutical distribution networks
- Approximately 1 billion patients annually
Fundamentals: Finnhub, as of 2026-07-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.